Abdominal/ Donor Site, DIEP or Free MS-TRAM Breast Reconstruction, Local Pain Management, Transversus Abdominis Plane (TAP) Block Catheter
Conditions
Brief summary
Breast reconstruction using a patient's own abdominal tissue is one of the most common methods for restoring mastectomy defects for breast cancer patients. Despite its increasing popularity and safety, the abdomen remains a major source of postoperative pain. Adequate pain control is important as it has been shown to reduce medical complications, in-hospital death, shortens hospital stay, lessen chronic pain and disability, and in turn lower health-care costs. The current postoperative pain relief protocol consists primarily of a patient-controlled anesthesia device delivering intravenous opioids. Opioids can cause numerous side-effects such as sedation, headache, nausea, vomiting, breathing difficulties, bladder and bowel dysfunction. A promising approach to provide postoperative pain control of the abdominal incision is the newly developed transversus abdominis plane (TAP) peripheral nerve block. Although the TAP block has been found to be an effective pain-relief following major abdominal surgeries, its use has never been studied for breast reconstruction using abdominal tissue. Therefore, the investigators propose to rigorously study the efficacy of a TAP block in reducing postoperative abdominal pain following abdominal tissue breast reconstruction. This study has significant implications in improving both clinical care and health outcomes in patients undergoing this common method of breast reconstruction technique.
Detailed description
1\. Statement of Objectives/Specific Aims The transversus abdominis plane (TAP) block is a newly developed block involving T6-L1 nerves that supply the anterior abdominal wall. Its effectiveness has been reported following major abdominal surgeries, but not following abdominally-based autologous tissue breast reconstruction. Thus, we propose a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of TAP block in improving pain symptomatology following abdominally-based, autologous tissue breast reconstruction. The primary objective of this study is to compare the mean total opioid consumption in the first postoperative 48 hours between the control and study groups in intravenous morphine equivalent units. By directly blocking the neural afferents, the mean opioid consumption will be significantly lower in the group receiving intermittent local anaesthetic boluses compared to the placebo group through a TAP catheter. The secondary outcomes of interest are to compare the following parameters: A. Continuous outcomes i. Total in-hospital cumulative opioid consumption ii. Total in-hospital cumulative anti-nausea consumption iii. Quality of Recovery (QOR) score (0-18) iv. Duration of hospital stay B. Repeated measures outcomes In Hospital postoperative measures: i. Daily pain intensity scores at rest and with movement using a visual pain analogue scale (0-10) ii. Postoperative nausea and vomiting (score of 0-3) iii. Sedation score Long-term chronic pain, anxiety, function, and quality of life (QOL) measures: iv. Pain disability index v. Short-form McGill Pain Questionnaire vi. Hospital Anxiety and Depression Scale vii. Short-form 36 C. Time to event outcomes i. Time to first bowel movement ii. Time to ambulation Hypothesis: Compared to the control group, the TAP block group will have a statistically significant reduction in total in-hospital consumption of opioids, pain scores and side-effects from opioid use such as sedation, nausea, and vomiting. This should also result in a greater QOR score in the TAP block group. Surgical milestones such as time to ambulation, first bowel movement, and duration of hospital stay will also be reduced in the TAP block group. In addition, we hypothesize less acute postoperative pain achieved using the TAP block will result in a reduction in chronic pain and disability, anxiety and depression, and improved QOL in the long-term.
Interventions
At the conclusion of the surgery, a 0.2 mL/kg bolus of 0.25% Bupivacaine will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of 0.25% Bupivacaine will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
At the conclusion of the surgery, a 0.2 mL/kg bolus of Saline will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of Saline will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
Sponsors
Study design
Eligibility
Inclusion criteria
-Pre-operative eligibility: * Patients above the age of 18, no upper age limit * English-speaking * Delayed reconstruction (mastectomy already performed) or immediate reconstruction (mastectomy at the same time as reconstruction) * Reconstruction using abdominal tissues including free MS-TRAM or DIEP
Exclusion criteria
* Patient refusal * Inability to give informed consent * BMI \> 40 * Allergy to Bupivacaine * Known cardiac or liver disease (contraindicated for Bupivacaine use) * Patients who will undergo any of the following: * Implant breast reconstruction * Combined implant and autologous tissue reconstruction * Non-abdominally based autologous tissue reconstruction * Nonmicrosurgical abdominally based breast reconstruction (pedicled TRAM flap) * Drug addiction * Opioid tolerance defined as preoperative opioid use of \>50 mg PO morphine equivalent * Psychiatric illness
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean Total Opioid Consumption | first postoperative 48 hours | The primary objective of this study is to compare the mean total opioid consumption in the first postoperative 48 hours between the control and study groups in intravenous morphine equivalent units. By directly blocking the neural afferents, the mean opioid consumption will be significantly lower in the group receiving intermittent local anaesthetic boluses compared to the placebo group through a TAP catheter. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Daily Pain Intensity Scores at Rest and With Movement | In Hospital postoperative measures, average 4-5 days | Daily pain intensity scores at rest and with movement using a visual pain analogue scale (0-10) |
| Pain Disability | Hospital discharge, average 4-5 days, 6 months and 1 year following discharge | Pain Disability Index Scores |
| First Bowel Movement | In-patient hospital stay, average 4-5 days | Time to first bowel movement (# of days) |
| Anti-nausea Consumption | In-patient hospital stay, average 4-5 days | Total in-hospital cumulative anti-nausea consumption |
| Quality of Recovery | In-patient hospital stay, first post operative 48 hours | Quality of Recovery (QOR) score (0-18) |
| Duration of Hospital Stay | In-patient hospital stay, average of 4-5 days | Duration of hospital stay (# of days) |
| Total In-hospital Cumulative Opioid Consumption | In-patient hospital stay average of 4 - 5 days | Total in-hospital cumulative opioid consumption levels |
| Sedation Level | In Hospital postoperative measures, average 4-5 days | Sedation score in-patient |
| Pain Frequency and Intensity | Hospital discharge, average 4-5 days, 6 months and 1 year following discharge | Short-form McGill Pain Questionnaire Score |
| Anxiety and Depression | Hospital discharge, average 4-5 days, 6 months and 1 year following discharge | Hospital Anxiety and Depression Scale Score |
| Health Related Quality of Life | Hospital discharge, average 4-5 days, 6 months and 1 year following discharge | Short-form health-related quality of life 36 Scores |
| Time to Ambulation | In-patient hospital stay, average 4-5 days | Time to ambulation (# of days) |
| Postoperative Nausea and Vomiting | In Hospital postoperative measures, average 4-5 days | Postoperative nausea and vomiting (score of 0-3) |
Countries
Canada
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Isotonic Saline (Control Group) At the conclusion of the surgery, a 0.2 mL/kg bolus of Saline will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of Saline will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off. | 44 |
| Bupivacaine (Study Group) At the conclusion of the surgery, a 0.2 mL/kg bolus of 0.25% Bupivacaine will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of 0.25% Bupivacaine will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off. | 49 |
| Total | 93 |
Baseline characteristics
| Characteristic | Isotonic Saline (Control Group) | Bupivacaine (Study Group) | Total |
|---|---|---|---|
| Age, Continuous | 50.5 years STANDARD_DEVIATION 8.4 | 52.1 years STANDARD_DEVIATION 8.3 | 51.4 years STANDARD_DEVIATION 8.3 |
| Region of Enrollment Canada | 44 participants | 49 participants | 93 participants |
| Sex: Female, Male Female | 44 Participants | 49 Participants | 93 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 2 / 44 | 3 / 49 |
| serious Total, serious adverse events | 0 / 44 | 0 / 49 |
Outcome results
Mean Total Opioid Consumption
The primary objective of this study is to compare the mean total opioid consumption in the first postoperative 48 hours between the control and study groups in intravenous morphine equivalent units. By directly blocking the neural afferents, the mean opioid consumption will be significantly lower in the group receiving intermittent local anaesthetic boluses compared to the placebo group through a TAP catheter.
Time frame: first postoperative 48 hours
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Isotonic Saline (Control Group) | Mean Total Opioid Consumption | 30.0 mg | Standard Deviation 19.1 |
| Bupivacaine (Study Group) | Mean Total Opioid Consumption | 20.7 mg | Standard Deviation 20.1 |
Anti-nausea Consumption
Total in-hospital cumulative anti-nausea consumption
Time frame: In-patient hospital stay, average 4-5 days
Anxiety and Depression
Hospital Anxiety and Depression Scale Score
Time frame: Hospital discharge, average 4-5 days, 6 months and 1 year following discharge
Daily Pain Intensity Scores at Rest and With Movement
Daily pain intensity scores at rest and with movement using a visual pain analogue scale (0-10)
Time frame: In Hospital postoperative measures, average 4-5 days
Duration of Hospital Stay
Duration of hospital stay (# of days)
Time frame: In-patient hospital stay, average of 4-5 days
First Bowel Movement
Time to first bowel movement (# of days)
Time frame: In-patient hospital stay, average 4-5 days
Health Related Quality of Life
Short-form health-related quality of life 36 Scores
Time frame: Hospital discharge, average 4-5 days, 6 months and 1 year following discharge
Pain Disability
Pain Disability Index Scores
Time frame: Hospital discharge, average 4-5 days, 6 months and 1 year following discharge
Pain Frequency and Intensity
Short-form McGill Pain Questionnaire Score
Time frame: Hospital discharge, average 4-5 days, 6 months and 1 year following discharge
Postoperative Nausea and Vomiting
Postoperative nausea and vomiting (score of 0-3)
Time frame: In Hospital postoperative measures, average 4-5 days
Quality of Recovery
Quality of Recovery (QOR) score (0-18)
Time frame: In-patient hospital stay, first post operative 48 hours
Sedation Level
Sedation score in-patient
Time frame: In Hospital postoperative measures, average 4-5 days
Time to Ambulation
Time to ambulation (# of days)
Time frame: In-patient hospital stay, average 4-5 days
Total In-hospital Cumulative Opioid Consumption
Total in-hospital cumulative opioid consumption levels
Time frame: In-patient hospital stay average of 4 - 5 days